Ivabradine Krka

Ivabradine, the active ingredient in Ivabradine Krka, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to manage chronic stable angina and heart failure in adult patients.

GNH USA supplies Ivabradine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in conditions where rate reduction improves outcomes.

Chronic stable angina: improves exercise tolerance and reduces the frequency of angina attacks. Heart failure (NYHA class II‑III): lowers heart rate, alleviates symptoms and may decrease hospitalisations. Ischemic heart disease: helps control heart rate when beta‑blockers are insufficient or not tolerated.

Ivabradine may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Bradycardia: heart rate falls below the desired range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Nausea or gastrointestinal discomfort.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Severe hypotension leading to syncope. - High‑grade atrioventricular block.

Before initiating therapy, clinicians should assess patient suitability and monitor for specific risks. - Heart rate monitoring: ensure resting heart rate remains above 50 bpm. - Hepatic impairment: use with caution in moderate to severe liver disease. - Concomitant bradycardic agents: avoid excessive heart‑rate reduction when combined with beta‑blockers or digoxin. - Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine can interact with several drug classes, influencing heart rate or plasma concentrations.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels. - Co‑administration with other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Other If‑channel inhibitors: additive effect on pacemaker activity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive drugs: potential additive blood‑pressure lowering. - QT‑prolonging agents: may increase arrhythmia risk, requiring ECG monitoring.